MONTREAL, QUEBEC and BOULDER, COLORADO--(Marketwire - January 09, 2008) - MethylGene Inc. (TSX: MYG) and Pharmion Corporation (NASDAQ: PHRM) today announced the enrollment of the first patient in a Phase II clinical trial (Trial 012) evaluating MGCD0103, the Companies’ isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Vidaza® (azacitidine for injection), Pharmion’s DNA demethylating agent, in patients with relapsed or refractory Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL).
